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Abstract: Sphingosine 1-phosphate (S1P) is a key bioactive lipid that regulates a myriad of
physiological and pathophysiological processes, including endothelial barrier function, vascular
tone, vascular inflammation, and angiogenesis. Various S1P receptor subtypes have been suggested
to be involved in the regulation of these processes, whereas the contribution of intracellular S1P
(iS1P) through intracellular targets is little explored. In this study, we used the human cerebral
microvascular endothelial cell line HCMEC/D3 to stably downregulate the S1P lyase (SPL-kd) and
evaluate the consequences on endothelial barrier function and on the molecular factors that regulate
barrier tightness under normal and inflammatory conditions. The results show that in SPL-kd
cells, transendothelial electrical resistance, as a measure of barrier integrity, was regulated in a
dual manner. SPL-kd cells had a delayed barrier build up, a shorter interval of a stable barrier,
and, thereafter, a continuous breakdown. Contrariwise, a protection was seen from the rapid
proinflammatory cytokine-mediated barrier breakdown. On the molecular level, SPL-kd caused
an increased basal protein expression of the adherens junction molecules PECAM-1, VE-cadherin,
and β-catenin, increased activity of the signaling kinases protein kinase C, AMP-dependent kinase,
and p38-MAPK, but reduced protein expression of the transcription factor c-Jun. However, the
only factors that were significantly reduced in TNFα/SPL-kd compared to TNFα/control cells, which
could explain the observed protection, were VCAM-1, IL-6, MCP-1, and c-Jun. Furthermore, lipid
profiling revealed that dihydro-S1P and S1P were strongly enhanced in TNFα-treated SPL-kd cells.
In summary, our data suggest that SPL inhibition is a valid approach to dampenan inflammatory
response and augmente barrier integrity during an inflammatory challenge.
Keywords: blood–brain barrier; endothelial integrity; inflammation; S1P lyase; junctional
molecules; PKC
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1. Introduction
The blood–brain barrier (BBB) is a unique barrier present in all mammals and is localized at
the interface between the blood and the central nervous system (CNS). It is an evolutionary trait
crucial for the maintenance of CNS homeostasis, by regulating the exchange of blood-borne molecules
and cellular elements [1,2]. This highly specialized structural and biochemical barrier is created by
endothelial cells that line the microvessels and differs significantly from non-CNS endothelial cells [3].
The BBB’s properties are primarily determined by junctional complexes between the endothelial cells,
which restrict the paracellular diffusion and preserve cell-cell contact [1]. BBB breakdown plays an
important role in the pathogenesis of many CNS diseases, ranging from trauma to neurodevelopmental
and neurodegenerative diseases, where proinflammatory substances or specific disease-associated
proteins often mediate endothelial dysfunction [4,5]. Accordingly, restoring the barrier integrity is
considered as a promising therapeutic approach, and several molecular pathways that regulate the
BBB function and integrity have been described in this context [6]. One of the pathways that has been
identified as a key determinant of BBB permeability is the sphingosine 1-phosphate (S1P) signaling
cascade [7].
S1P is the central lipid molecule in the sphingolipid catabolism, which is generated by
phosphorylation of sphingosine by the action of sphingosine kinase (SK)-1 and -2 [8]. The physiological
importance of S1P is substantial, since it is ubiquitously distributed [9] and regulates a myriad of
cellular responses, including survival, proliferation, migration, and differentiation [10]. S1P primarily
acts as an extracellular high-affinity ligand and an activator of the five G protein-coupled receptors
named S1P1–5 [11]. Signaling downstream of the S1P receptors modulates lymphocyte trafficking,
vascular tone, vascular barrier function, cardiac development, and many other critical processes [12].
Furthermore, S1P can act as an intracellular second messenger to antagonize apoptotic signals and
regulate the Ca2+ homeostasis [13]. However, these intracellular functions are not fully understood,
and direct targets are still elusive.
To preserve the intracellular sphingolipid balance, which is known as “sphingolipid rheostat”,
the cells exploit a series of enzymes that reversibly backconvert S1P to sphingosine, including lipid
phosphate phosphatases and S1P phosphatases, or that irreversibly degrade S1P to hexadecenal and
ethanolamine-phosphate and thereby terminate signaling. The latter is catalyzed by the endoplasmic
reticulum-resident enzyme S1P lyase (Sgpl1, SPL) [14,15].
Several S1P receptors have been suggested to be involved in the development and maintenance of
endothelial barrier properties. S1P in the blood at physiological concentrations activates S1P1 on the
endothelial cells and induces barrier enhancement [7,16] by the modulation of cytoskeletal forces [17]
and the redistribution of tight junction proteins [18]. S1P5 expressed on brain endothelial cells also
contributes to optimal barrier formation [19], while an opposite function was described for S1P2, which
induces stress fiber formation and prevents the proper localization of cell–cell junctions, resulting in
enhanced barrier permeability [20]. S1P3 seems to act in a similar fashion as S1P2, as S1P3 inhibition
functionally tightens the blood–tumor barrier in brain metastases [21], whereas S1P3 ligation, following
intratracheal delivery of S1P, causes pulmonary edema via endothelial/epithelial barrier disruption [22].
Obviously, an important component of the mechanism of the action of extracellular S1P (eS1P) is the
intercellular junctional complexes, which include the adherens and tight junction molecules and also
several adhesion proteins outside of the specialized junctional complexes.
In contrast to the vast knowledge about the S1P receptor-mediated functions of eS1P, much less is
known about the effects of the intracellular S1P (iS1P) in endothelial cells and, in particular, the impact
on barrier function. In the present study, we used an SPL knockdown (kd) approach in endothelial
cells derived from the BBB, HCMEC/D3, to evaluate the implications of increased intracellular S1P
levels on endothelial phenotype markers, responses to inflammatory stimuli, and the consequences on
barrier tightness. As the reports on SPL involvement in endothelial function are sparse and mainly
derived from endothelial cells from non-CNS vascular beds, this is the first study that investigates the
vasculoprotective role of SPL in the brain endothelium under inflammatory conditions.
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In this study, we demonstrate that, in S1P lyase (SPL-kd) cells, transendothelial electrical
resistance, as a measure of barrier integrity, was regulated in a dual manner. Unstimulated SPL-kd
cells had a more destabilized barrier, whereas in an inflammatory setting, SPL-kd mediated protection
from proinflammatory cytokine-mediated barrier breakdown. We show that SPL-kd resulted in a
substantial accumulation of intracellular S1P and dihydro-S1P and various other molecular factors
that could contribute to the protective effect. These data suggest that SPL modulation is a valid
approach to dampen an inflammatory response and enhance barrier integrity during an inflammatory
challenge in brain endothelial cells. Finally, they provide a clue how to treat diseases characterized by
inflammation-mediated BBB disruption.
2. Results
Many studies have shown that S1P helps to maintain vascular endothelial barrier integrity which
mainly occurs through S1P receptor signaling. In order to evaluate the effect of intracellular S1P on
BBB function, we stably downregulated SPL in the human cerebral microvascular endothelial cell line
HCMEC/D3 by transduction of cells with a lentiviral construct containing SPL-specific shRNA or an
empty vector as a control. Knockdown efficiency was 99% on the SPL protein level (Figure 1A) and
95% on the mRNA level (Figure 1B). Interestingly, SPL-kd cells changed their morphology from a
typical cobblestone shape to a rather spindle-shape phenotype (Figure 1C). To further characterize the
SPL-kd cells, cellular S1P and dihydro-S1P were quantified by mass spectrometry. The results show an
approx. 6-fold increase of iS1P in the SPL-kd cells as compared to the control cells (Figure 1D) and a
small, but significant, change in the levels of dihydro-S1P (Figure 1E). When exogenous sphingosine
was added to ensure sufficient substrate for SKs, endogenous S1P accumulated manifold and further
increased by SPL-kd (Figure 1D).
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Proteins and RNA were extracted and taken for either a Western Blot analysis of the SPL protein (A), 
or a qPCR analysis of SPL mRNA (B). (C) Subconfluent cells grown on gelatin-coated dishes were 
photographed using a light microscope (Zeiss AxioObserver Z1, Feldbach) with a 200× total 
magnification and phase contrast setting. (D,E) Control (ctrl) and SPL-kd cells were rendered 
serum-free for 24 h and were treated for the last 10 min with either vehicle (-) or 1 μM of sphingosine 
(sph). The lipids were then extracted and processed for LC-MS/MS as described in the Methods 
section. The results in A and B are expressed as % of the control transduced cells and are depicted as 
means ± S.D. (n = 3 in A, n = 4 in B, *** p < 0.001). Results in D and E are expressed as pg/1,5 × 106 cells 
and are means ± S.D. (n = 3; * p < 0.05, ** p < 0.01, **** p < 0.0001 considered statistically significant 
when compared to the vehicle-treated control; # p < 0.05 compared to the sphingosine-treated control; 
§ p < 0.05, §§ p < 0.01 compared to the vehicle-treated SPL-kd). 
Figure . Characterization of a stable SPL knockdo n i / ll . HCMEC/D3 cells,
transduced with either an empty lentiviral vector (ctrl) or a lentiviral vector containing SPL shRNA
(SPL-k ), r cultured until confluence and were th n incubated for 4 h in serum-free DMEM. Proteins
and RNA were extracted and taken for either a Western Blot analysis of the SPL protein (A), r a qPCR
analysis of SPL mRNA (B). (C) Subconfluent cells grow on gelatin-coated dishes were photographed
using a light microscope (Zeiss AxioObserver Z1, Feldbach) with a 200× total magnification and phase
contrast setting. (D,E) Control (ctrl) and SPL-kd cells were rendered serum-free for 24 h and were
treated for the last 10 min with either vehicle (-) or 1 µM of sphingosine (sph). The lipids were then
extracted and processed for LC-MS/MS as described in the Methods section. The results in A and
B are expressed as % of the control transduced cells and are depicted as means ± S.D. (n = 3 in A,
n = 4 in B, *** p < 0.001). Results in D and E are expressed as pg/1,5 × 106 cells and are means ± S.D.
(n = 3; * p < 0.05, ** p < 0.01, **** p < 0.0001 considered statistically significant when compared to the
vehicle-treated control; # p < 0.05 compared to the sphingosine-treated control; § p < 0.05, §§ p < 0.01
compared to the vehicle-treated SPL-kd).
Int. J. Mol. Sci. 2020, 21, 1240 4 of 19
In order to detect the differences in the endothelial barrier integrity of HCMEC/D3 control and
SPL-kd cells, an electric cell-substrate impedance sensing (ECISTM) assay was used. First, an initial cell
number titration was performed to determine the optimal cell number and time frame of the assay.
Control HCMEC/D3 and SPL-kd cells were seeded with a density between 20,000 and 50,000
cells/mL to determine a cell concentration resulting in a stable, long-term barrier function. All cell
densities of tested control cells showed a long-term, stable barrier function after 96 h (Figure 2).
In contrast, SPL-kd cells reached a short barrier plateau (12 h duration) with a subsequent barrier
breakdown (Figure 2). As a stable barrier function developed at a cell density of 50,000 cells/mL in
both cell types during an overlapping time interval, this density was chosen for further experiments.
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Figure 2. Cell number titration of HCMEC/D3 control and SPL-kd using ECISTM. HCMEC/D3 control
cells (continuous lines) and SPL-kd cells (dashed lines) were seeded at densities between 20,000 and
50,000 cells/mL. ECISTM measurements were monitored over an observation period of 216 h and were
performed as described in detail in the Methods section. Partial medium changes were performed
every 24 h until t = 72 h. The data are shown as mean curves of triplicate samples.
Proinflammatory factors, including the bacterial product lipopolysaccharide (LPS) and cytokines
such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and interferon (IFN)-γ, are known
to affect the stability of endothelial barriers. To elucidate the impact of inflammatory stimuli on
HCMEC/D3 control and SPL-kd cells, we performed a dose-response experiment (1:100, 1:400, 1:800
and 1:1000) using ECISTM (Figure 3). After 24 h, we observed a significant decrease of resistance only
in control cells induced by a dilution of 1:100 of LPS plus cytokine mix (LPS + Cyt), indicating an initial
barrier breakdown, whereas both cell types showed no decline of resistance at LPS + Cyt dilutions
of 1:400, 1:800, and 1:1000. At 120 h after administration of the inflammatory stimulus, we observed
an on-going barrier breakdown in HCMEC/D3 cells by LPS + Cyt 1:100. However, also, the higher
LPS + Cyt dilutions caused significantly extenuated barrier stability in HCMEC/D3 cells. As seen
before, SPL-kd without LPS + Cyt could not maintain barrier stability on a long-term basis; only when
applying inflammatory stimuli, SPL-kd significantly strengthened the endothelial barrier (Figure 3).
We further investigated whether SPL-kd cells are differentially equipped with junctional molecules,
which could explain the observed phenotype in barrier integrity. The expression of various adherens
junction molecules under resting and inflammatory conditions was evaluated. As seen in Figure 4
and Figure S1, SPL-kd cells showed an increased basal protein expression level of the platelet and
endothelial cell adhesion molecule (PECAM-1) compared to the control cells, which is reduced upon
stimulation with the proinflammatory cytokine TNFα but still remained at a much higher level in
SPL-kd cells than in the control cells. Vascular endothelial cadherin (VE-cadherin) and β-catenin were
also increased by SPL-kd but were not altered by TNFα stimulation. The levels of p120 catenin and the
adaptor protein zonula occludens-1 (ZO-1) were not affected by SPL-kd or TNFα. The increased protein
expression of PECAM-1 and VE-cadherin was in line with the increased mRNA expression by the
SPL-kd (Figure S2A,B), whereasβ-catenin mRNA (Figure S2C) was not significantly changed by SPL-kd
or by TNFα. However, since one of the downstream targets of β-catenin, Axin2 [23], was upregulated
by SPL-kd and reduced by TNFα on mRNA level (Figure S2D), we conclude that the regulation of
β-catenin by SPL-kd occurs on the post-translational level and has downstream consequences.
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time points 24 h and 120 h (indicated by dotted arrows) after LPS + Cyt administratio . The ata are
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Figure 4. Effect of SPL knockdown on the expression of adherens junction molecules in TNFα-stimulated
HCMECs. Confluent control (ctrl) and SPL-kd HCMEC/D3 cells were incubated for 4 h in ser m-free
DMEM b fore stimulation for 24 h with either vehicle (-) or 1 nM TNFα in DMEM/0.1% FBS. The
protein were extracted, separated by SDS-PAGE, transferred to nitrocellulose membrane and subjected
to analysis usi g antibodies agai st PECAM-1, VE-c dh rin, β-catenin, p120, ZO-1 an α-tubulin. Data
show epresentative blots, out of 3 indepe dent experim nts, performed in triplicates. Th evaluation
of the espective bands is pr s nted in Figure S1.
Furthermore, in endothelial cells, TNFαmarkedly induces the synthesis of intercellular adhesion
molec le 1 (ICAM-1) a vascular cell adhesion mol cule 1 (VCAM-1), which are both known to
facilitate leukocyte transmigration [24]. Here, TNFα stimulation resulted in a strong induction of
ICAM-1 (Figure 5A, Figure S3A) and VCAM-1 protein (Figure 5A, Figure S3B) as well as of their mRNA
expressions (Figure 5B,C). We found that in SPL-kd cells, only VCAM-1 expression, but not ICAM-1,
was significantly reduced by SPL-kd, suggesting a potential attenuation of leukocyte recruitment in
SPL-kd. Moreover, gene expres ion of inflammatory products incl ding monocyt chemoattractant
protein 1 (MCP-1/CCL2), IL-6 and IL-8, were all induced by TNFα treatment, but only MCP-1 and IL-6
Int. J. Mol. Sci. 2020, 21, 1240 6 of 19
were significantly downregulated in SPL-kd cells (Figure 6A–C), whereas IL-8 expression was rather
enhanced by SPL-kd (Figure 6D).
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Figure 5. Effect of TNFα stimulation on the protein and mRNA expression of adhesion molecules in
control and SPL-kd HCMEC/D3. Confluent control (ctrl) and SPL-kd HCMEC/D3 cells were rendered
serum-free for 4 h prior to stimulation for 24 h with either vehicle (−) or 1 nM TNFα in DMEM/0.1%
FBS. Thereafter, cells were taken for either protein extraction and Western Blot analysis of ICAM-1,
VCAM-1, and α-tubulin (A), or RNA extraction and qPCR analysis of ICAM-1 and VCAM-1 (B,C).
The results are expressed as % of control transduced cells and are means ± S.D. The evaluation of the
respective bands (A) is presented in Figure S3. (n = 3 for A, n = 4–6 for B–C; **** p < 0.0001 compared to
the vehicle-treated control; # p < 0.05 compared to the TNFα-treated control; § p < 0.05, §§§§ p < 0.0001
compared to the vehicle-treated SPL-kd).
To further delineate the mechanism of the SPL-kd-mediated protection of barrier integrity under
inflammatory conditions, we investigated various key signaling cascades and transcriptions factors.
VCAM-1, MCP-1, IL-6, and IL-8 are all known to be critically regulated by the transcription factor
nuclear factor κB (NFκB). In view of a previous report showing that intracellular S1P can directly bind
to the TNF receptor-associated factor 2 (TRAF2) and trigger NFκB activation [25], we here determined
whether NFκB was affected by SPL-kd. Phosphorylation of the p65 subunit of NFκB occurs upon TNFα
stimulation and precedes the nuclear translocation and transcriptional regulation of target genes [26].
In SPL-kd cells, we did not observe any difference in TNFα-stimulated p65-NFκB phosphorylation
compared to the control cells (Figure S4), thus excluding a link between iS1P and NFκB activation in
this HCMEC system.
Two protein kinases that showed enhanced phosphorylation and activity by SPL-kd were
p38-MAPK and the AMP-activated protein kinase (AMPK) (Figure 7A). Additionally, the total protein
expression level of the transcription factor c-Jun, as well as its phosphorylation at Ser63 were reduced in
SPL-kd, whereas JunB was not altered (Figure 7A). No significant changes in phospho-p42/p44-MAPK,
phospho-Akt, and phospho-SAPK/JNK were observed by SPL-kd (Figure S5). Other transcription
factors, including KLF2 and KLF4, which are considered as “molecular switches” regulating important
aspects of vascular function and leukocyte adhesion [27,28], were found to be enhanced on the mRNA
level but unchanged on the protein level (Supplementary Figure S6). Interestingly, the protein kinase C
(PKC) family was also found to be activated by SPL-kd. Since PKC consists of at least 11 isoenzymes,
and so far single isoenzyme’s activities cannot be measured in cellular systems, we analyzed the
total cellular PKC activity by determining the phosphorylation pattern of PKC substrates using a
phospho-specific PKC substrate and a phospho-MARCKS antibody (Figure 7B). Notably, two bands of
approx. 30 kDa and 40 kDa were clearly upregulated by SPL-kd and a similar pattern was observed
for the major PKC substrate, MARCKS. These bands were also upregulated by short-term phorbol
ester (TPA) stimulation.
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Figure 7. Effect of SPL-kd on various signaling molecules and transcription factors. Confluent control
(ctrl) or SPL-kd HCMEC/D3 cells were rendered serum-free for 4 h prior to stimulation with either vehicle
(−), 1 nM TNFα (A) or 50 nM TPA (B) in serum-free DMEM for 10 min. Protein extracts were separated
by SDS-PAGE and subjected to Western blot analysis using antibodies against phospho-p38-MAPK,
total p38-MAPK, phospho-AMPKα, total AMPKα, phospho-c-Jun, total c-Jun, JunB, phospho-protein
kinase C (PKC) substrates, phospho-MARCKS, and α-tubulin. The data show representative blots, out
of 3–4 independent experiments, performed in triplicates.
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A previous study reported that iS1P can directly inhibit histone deacetylases (HDACs) [29] and
that, by such epigenetic interference, iS1P may regulate the expression of various genes. We therefore
tested here whether SPL-kd affects overall cellular HDAC activity by using an in situ fluorometric
assay and by detecting histone H3 lysine 3 acetylation, as the most reported residue connected to iS1P,
by Western Blot analysis. However, in SPL-kd cells, no change in either overall cellular HDAC activity
(Figure S7A) or in acetylated histone H3 (Figure S7B) as a target of HDAC1/2 occurred.
To further investigate whether certain sphingolipid species are differentially affected by TNFα
treatment in SPL-kd cells, lipid extracts of cells were quantified by mass spectrometry. S1P levels,
which were markedly enhanced in SPL-kd cells, were only slightly increased by TNFα treatment
in control cells but showed a synergistic increase in TNFα plus SPL-kd (Figure 8A). Dihydro-S1P
showed a similar regulation and was also synergistically increased by TNFα plus SPL-kd (Figure 8B).
The precursor of these lipids, sphingosine, was also increased, whereas sphinganine and many
ceramides and glycosylated ceramides were rather downregulated (Table S1). This lipid pattern
suggests a negative feedback in the de novo pathway with a potential impact on SK-1 expression,
which is downregulated on both the protein and mRNA level (Figure S8), possibly as a mechanism to
divert sphingosine from further S1P production.
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control (ctrl) and SPL-kd cells were rendered serum-free for 24 h prior to stimulation for 24 h with either
vehicle (−) or 1 nM TNFα. Lipids were extracted and quantified by LC-MS/MS. The results are depicted
as picograms per 1.5 × 106 cells and are means ± S.D. (n = 3; * p < 0.01, ** p < 0.001, **** p < 0.0001
considered statistically significant when compared to the vehicle-treated control; #### p < 0.0001
compared to the TNFα -treated control; §§§§ p < 0.01 compared to the vehicle-treated SPL-kd).
Finally, to study the role of extracellular S1P on the barrier integrity of HCMEC/D3 control and
SPL-kd cells, we performed a pre- and post-treatment with S1P (10 nM and 100 nM) using the ECISTM
system to examine the ability of S1P to ameliorate barrier dysfunction induced by an inflammatory
stimulus. Pre-treatment with S1P, given 4 h prior to LPS + Cyt stimulation, did not affect barrier
stability in either cell types over the whole time period (Figures S9 and S10). Conversely, post-treatment
with S1P, given 24 h after LPS + Cyt stimulation, significantly attenuated LPS + Cyt-induced barrier
destabilization in control HCMEC/D3 cells, but this was only seen after 120 h (Figures S11 and S12).
No effect of post-treatment with S1P was seen in SPL-kd cells (Figures S11 and S12) or with S1P alone
in both cell lines (Figures S9–S12).
3. Discussion
In the present study, we demonstrate that the genetic knockdown of SPL in the human cerebral
microvascular endothelial cell line HCMEC/D3 alters barrier function, which occurs in a dual
manner. Under inflammatory conditions, which normally trigger a continuous and long-lasting
barrier breakdown (Figure 3), SPL-kd demonstrated consolidated barrier function. However, under
unstimulated conditions of endothelial junctional assembly, SPL-kd cells had a delayed barrier build up,
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a shorter stable barrier plateau and thereafter a continuous breakdown (Figure 2). Obviously, SPL-kd,
which primarily leads to enhanced iS1P levels, can have both barrier-protective and barrier-disruptive
effects, depending on the milieu.
Increased endothelial permeability is considered a serious complication in many inflammatory
diseases or as a factor that contributes to the pathology of neurodegenerative diseases, trauma,
tumors, and ischemia. Such endothelial dysfunction may be induced by various factors, for instance,
inflammatory cytokines, histamine, thrombin, LPS, vascular endothelial growth factor, and
bradykinin [30–32]. Although these permeability-inducing factors bind to different receptors, their
signaling converges mainly on the level of the adherens junction molecules VE-cadherin, β-catenin,
and PECAM-1, which become disrupted due to downregulated expression or enforced internalization
through phosphorylation, resulting in a diminished interaction with other junctional molecules and
the actin cytoskeleton, reduced enrichment on cell-cell borders, and an overall decrease in the adhesion
strength [30,31,33,34].
The protective effect of S1P on the endothelial barrier is well reported and has been confirmed
in vitro in cell cultures of endothelial cells but also in vivo in the vasculature [35,36]. Upon S1P
stimulation, there is a rapid strengthening of the barrier that involves various mechanisms, including
Rac1 activation, phosphorylation of actin-binding proteins of the ezrin/radixin/moesin family, and
the rearrangement of cytoskeletal proteins to the cell periphery [35,37]. Additionally, S1P can
increase the expressions of VE-cadherin and PECAM-1 in human endothelial cells and decrease the
phosphorylation-induced VE-cadherin/catenin complex destabilization [38–40]. These effects of eS1P
are mediated by S1P receptors, of which most evidence is presented for S1P1 [38,41,42], but other
receptor subtypes, such as S1P3 [43] and S1P5 [19], may also mediate protection. In opposition to this,
a rather barrier disruptive function of S1P through S1P2 [20] and S1P3 [21,44] has also been described.
Our data now demonstrate that iS1P is also an important for the barrier function and affects the
BBB, as seen in vitro in endothelial cells originating from BBB. SPL-kd, which results in increased
iS1P (Figure 1D), has immediate consequences on the protein expression of various adherens
junctions, signaling molecules, and transcription factors, which may promote barrier protection
under inflammation. These include an increased expression of VE-cadherin, PECAM-1 and β-catenin
(Figure 4), and an increased activation state of PKC, AMPK, and p38-MAPK but a reduced expression
of the transcription factor c-Jun (Figure 7). Upon TNFα treatment, SPL-kd cells demonstrated a strong
downregulation of the adhesion molecule VCAM-1 (Figure 5) and the cytokines IL-6 and MCP-1
(Figure 6), all of which could contribute to the protective effect under inflammatory conditions. In this
view, it is known that VCAM-1 is upregulated by pro-inflammatory cytokines, and upon VCAM-1
cross-linking, which mimics clustering with integrins on leukocytes, signaling is induced that increases
stress fiber formation and barrier opening [45,46]. IL-6 promotes a sustained loss of endothelial
barrier function via JNK-mediated STAT3 phosphorylation and de novo synthesis [47], while MCP-1
(CCL2) acts in an autocrine manner on the endothelial CCR2 receptor to disrupt tight and adherens
junctions [48,49]. Whether the increased IL-8 synthesis in SPL-kd cells has any clinical relevance is
presently unclear, but remarkably, a previous study [50] also showed that a similar effect occurred
in placentas of preeclampsia patients, which expressed less SPL and had higher IL-8 levels in the
circulation [50].
Although these factors are classically regulated by NFκB, we could not see any change in
NFκB activity in the SPL-kd (Figure S4), and therefore the mechanism of downregulation by SPL-kd
remains unclear. Krüppel-like factors (KLF) are reported to inhibit the transcriptional activity of
NF-κB by competing for its transcriptional coactivators and thereby down-regulating its expression
of proinflammatory genes [51]. For instance, KLF2 is known as a key transcriptional regulator of
endothelial proinflammatory activation, by the inhibition of the cytokine-mediated induction of
VCAM-1 expression, without affecting the expression of ICAM-1 and, similarly, the depletion of
KLF4 acted proinflammatory by the enhancement of TNFα-induced VCAM-1 expression [52,53].
Although we detected significantly higher mRNA levels of KLF2 and KLF4, their protein levels
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remained equal between control and SPL-kd cells (Figure S6). Therefore, the contribution of KLF2
and KLF4 for the observed anti-inflammatory response in the SPL-kd cells can be excluded. We also
identified the transcription factor c-Jun to be significantly reduced in SPL-kd (Figure 7A). We therefore
speculate that this reduction of c-Jun at least partially contributes to the observed barrier protection.
This is in agreement with a previous study that specifically targeted c-Jun expression, which resulted
in the suppression of vascular permeability and inflammation [54]. It is also likely that the diminished
expression of c-Jun accounts for the lower expression of VCAM-1, as it was shown that the AP-1
complex mediates the effect of TNF-α in the regulation of VCAM-1 expression through the modulation
of the NF-κB transactivation in endothelial cells [55]. In addition, p38-MAPK may independently
or synergistically regulate the effects of TNFα, and it was demonstrated that the inhibition of this
kinase suppressed the TNFα-induced expression of VCAM-1 without affecting ICAM-1 and that this
stress kinase cascade is critical for the TNFα-induced expression of MCP-1 in endothelial cells [56,57].
This clearly opposes our findings, as we found a constitutive increase in p38-MAPK with a decreased
basal production of MCP-1 and TNFα-induced VCAM-1, which corroborates the controversial role of
the p38 pathway [58].
The barrier-protective effect of iS1P is in agreement with a previous study by Li et al. [59],
who showed that mice transgenic for SK-1 in endothelial cells have a reduced vascular leakiness upon
angiopoietin-1 treatment, and that this protective effect is independent of eS1P and S1P receptors.
This was further confirmed by Zhao et al. [60] in another approach of targeting the degrading enzyme
SPL. They showed that in human lung microvascular endothelial cells, or in heterozygous SPL (+/-)
mice, the loss of SPL reduced LPS-triggered barrier breakdown and pulmonary permeability. The
authors also suggested that the protection from lung endothelial barrier disruption is mediated
by accumulated iS1P and requires coupling to S1P1 and subsequent Rac1 activation. Obviously,
there is an inconsistency whether iS1P acts dependent on S1P receptors or not. Moreover, a study
using intravital microscopy in a murine atherosclerosis model revealed that iS1P reduced leukocyte
adhesion to capillary wall and decreased LPS-induced endothelial permeability [61], thus corroborating
our findings.
In opposition to the restorative effect of SPL-kd in an inflammatory setting, our data show a
barrier-disruptive effect of SPL-kd in the early phase of barrier build up. Biphasic barrier regulation
has also been reported by other stimuli. In this regard, an androgen-like steroid, LPS, and cyclic
nucleotides, demonstrated a dual manner of barrier regulation, which is concentration dependent
and involves changes in the actin cytoskeleton, protein kinase A, and PI3K/Akt pathways among
others [62–65]. Although SPL-kd cells possess enhanced expression of several factors important for
barrier consolidation, these factors are not, per se, sufficient to support the barrier function in the initial
phase of junctional assembly, and the mechanism of this is still unclear.
Various mechanisms can contribute to the basal assembly of endothelial junctions and among these
are calcium and multiple protein kinases, including PKC, AMPK, protein kinase A, myosin light-chain
kinase, non-receptor tyrosine kinases, and Rho-dependent kinase [66–68]. For instance, PKC and
intracellular Ca2+ [69] were reported to promote junction assembly in MDCK cells, whereas already
assembled junctions are destabilized by factors such as thrombin through PKC activation and increased
intracellular Ca2+ [70]. Since SPL knockout in mouse embryonic fibroblasts (MEF) has been shown to
enhance intracellular calcium levels [71,72], and since the inhibition of S1P synthesis by sphingosine
kinase inhibition decreases Ca2+ mobilization and permeability in human umbilical vein endothelial
cells [73], it is well conceivable that also in HCMECs, the downregulation of SPL causes changes in
intracellular Ca2+ levels, which could regulate junctional assembly and disassembly. As conventional
PKCs are usually activated by Ca2+, we studied the pattern of PKC substrates’ phosphorylation and
MARCKS phosphorylation and could indeed see changes in PKC activity (Figure 7B). Notably, the
phosphorylations of 30 kDa and 40 kDa substrates were increased in SPL-kd, suggesting that iS1P
may either directly or indirectly activate PKC. This dual effect of PKC can be explained by the fact
that PKC is not just one entity, but rather a family consisting of 11 different isoforms, which can
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exert diverse and even opposite functions. In this regard, PKC-α, PKC-β, -θ, and −ζ activities were
attributed to increased endothelial permeability [74–77], whereas PKC-δ and PKC-ε can mediate barrier
protection [78,79]. It is also worth noting that in the livers of SPL-deficient mice [80] and in MEFs
isolated from SPL-deficient mice [81], diacylglycerols, which are well known direct PKC activators,
were reported to be significantly increased, thus further supporting the conclusion that SPL-kd couples
to enhanced PKC activity.
To examine the efficacy of S1P to ameliorate the barrier dysfunction induced by an inflammatory
stimulus, we performed a pre- and post-treatment with S1P. Our data show that in control HCMEC/D3
cells, eS1P by itself, or eS1P added as a stimulus prior to an inflammatory mixture, could not strengthen
the endothelial barrier. Only in an inflammatory setting, post-treatment with eS1P had a protective
effect on the cytokine-induced barrier breakdown (Figures S11 and S12). Notably, this protective effect
was seen at a late time point (120 h), but not at early time points (48 h). It may be speculated that
this phenomenon is mediated by gene transcriptional mechanisms and de novo protein synthesis,
which are triggered by eS1P and require a prolonged period until detection. The protective effect of
post-treatment eS1P in the inflammatory setting was abolished in the SPL-kd cells (Figures S11 and
S12), suggesting that either the expression of S1P receptors are altered by the knockdown and thus the
responsiveness towards eS1P or that the barrier improving effect by SPL-kd is already maximal and
cannot be further enhanced by additional eS1P. In this context, it is of interest that the barrier improving
effect of eS1P cannot be seen in all types of endothelial cells. In a comparative study between dermal
microvascular endothelial cells (HMEC-1) and glomerular endothelial cells (GENC), it was shown that
eS1P could only improve the barrier function in HMEC-1, but not in GENC [82]. The protective effect
was dependent on the ability of eS1P to stimulate AMPK, which was seen in HMEC-1 but not in GENC.
To see whether the protective effect of SPL-kd under inflammatory conditions correlates with a
change in certain sphingolipid subspecies, a more extended analysis of sphingolipids was performed
by LC-MS/MS (Figure 8 and Table S1). Previous studies demonstrated that not only S1P, but also other
sphingolipid molecules, such as sphingomyelin [83], ceramides, and very long-chain ceramides [84,85],
are involved in endothelial barrier regulation. In agreement with this, other sphingolipid species may
mediate the response towards inflammatory stimuli, as we have seen from the LC-MS/MS data that S1P
and dihydro-S1P, which are both modestly increased by TNFα in control cells, synergistically increase
by TNFα in SPL-kd (Figure 8). Ceramides of various chain lengths were decreased in HCMEC/D3
SPL-kd (Table S1), which is in accordance to a previous study in SPL-deficient Hela cells [81]. According
to Linder et al. [84], ceramides have the potential to alter endothelial cell permeability. Nevertheless,
S1P and dihydro-S1P remain the only measured sphingolipids showing a unique pattern of increase in
SPL-kd cells under inflammatory conditions. Since several studies have indicated a positive correlation
between reduced dihydro-S1P and reduced endothelial barrier function [86], further investigation
is required to elucidate to what extent dihydro-S1P is involved in the biphasic resistance response
of SPL-kd.
Although most of the BBB characteristics are determined by endothelial cells, they coexist
with pericytes and astrocytes and the surrounding extracellular matrix which maintain their
characteristics [87]. Since our data were generated in immortalized brain endothelial cells, this
bears the risk of undermining the barrier attributes that emanate from the continuous crosstalk of
endothelial cells with mural and glial cells. Thus, it would be important to validate our findings in a
co-culture system and expand our analysis on the tight junctions, which are crucial for BBB integrity.
Altogether, our data suggest that SPL inhibition is a valid approach to dampen an inflammatory
response and increase barrier integrity during an inflammatory challenge in brain endothelium and it
provides a clue how to treat diseases characterized by inflammation-mediated BBB disruption.
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4. Materials and Methods
4.1. Chemicals
All chemicals, primer sequences, and commercial and in-house produced antibodies, are indicated
in the supplementary data file.
4.2. Cell Culturing and Stable SPL Knockdown Generation
Immortalized human cerebral microvascular endothelial cell line (HCMEC/D3) was purchased
from CELLutions Biosystems Inc., Ontario, Canada (Catalogue Number: CLU512) and was maintained
according to manufacturer’s instructions, with the variation of using DMEM as basal medium
supplemented with 5% FBS from PAN-Biotech, 1.4 µM hydrocortisone, 5 µg/mL ascorbic acid, 5 mL
CD lipid concentrate, 10 mM HEPES, and 1 ng/mL bFGF. Cells were passed 2–3 times a week, using
Trypsin-EDTA 0.25% for dissociation, and were used within passages 27–40. Flasks were pre-coated
with autoclaved 1% gelatin in phosphate-buffered saline (PBS) and incubated for 1 h in incubator to
allow polymerization.
The stable knockdown of SPL in HCMECs was achieved by transduction with lentiviral
short hairpin RNA (shRNA) construct from Sigma MISSION® following the respective protocols.
Two different constructs were tested in parallel (TRCN0000286832 and TRCN0000078314), and the clone
that yielded strongest gene silencing (TRCN0000286832) was used further. Cells were further named
SPL-kd. Virus control cells were generated with TRC2 pLKO.5-puro empty vector control plasmid
DNA from the same company. For the selection of resistant colonies, 1.5 µg/mL of puromycin was
added to the medium in accordance with the results from previous titration. Knockdown efficiency was
confirmed by quantitative PCR, Western Blot analysis, and by an LC-MS/MS to determine intracellular
S1P accumulation.
All cells were cultured in the environment of 37 ◦C in an atmosphere enriched with 5% CO2.
Prior to stimulation, they were rendered serum-free for 4 h or 24 h with a medium consisting of DMEM,
0.1 mg/mL BSA, and 10 mM HEPES (later on referred as DMEM serum-free), unless otherwise stated.
4.3. Western Blot Analysis
Stimulated cells were washed with ice-cold PBS and were subsequently scraped with lysis buffer
(50 mM Tris-HCl pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton X100, 2 mM EDTA pH 8.4, 2 mM EGTA
pH 8.0, 40 mM β-glycerol phosphate, 50 mM NaF, 10 mM sodium pyrophosphate, 2 mM DTT, 200 µM
Na3VO4, 400 µL reconstituted cOmplete™ protease inhibitor cocktail, and 10 µM PMSF). Cells were
homogenized by sonication (5 s at 30 microns peak to peak amplitude; n. Zivy & Co Ltd., Oberwil,
Switzerland), lysates were centrifuged for 10 min at 13,000 rpm, and the supernatant was taken for
protein determination according to Bradford. The samples were dissolved in Laemmli buffer separated
by SDS-PAGE followed by protein transfer to nitrocellulose membrane by wet blotting using a buffer
containing 25 mM Tris, 190 mM glycine and 20% (v/v) methanol. Membranes were blocked with 3%
(w/v) low-fat milk powder in PBS for 1 h and were then incubated with the respective antibodies and
diluted in a buffer containing 50 mM Tris-HCl pH 7.4, 200 mM NaCl, 10% (v/v) horse serum, 3% (w/v)
BSA fraction V, and 0.1% (v/v) Tween20.
4.4. RNA Extraction and Quantitative PCR Analysis
Stimulated cells were washed with ice-cold PBS and homogenized in RNA-Solv® reagent. Total
RNA extraction was performed according to the instructions of the manufacturer. The yield and
purity of the isolates were assessed with a NanoDrop® ND-1000 spectrophotometer (Witec AG, Littau,
Switzerland), and first strand cDNA was synthesized using 1 µg total RNA as template. SYBR®
Green-based quantitative PCR was performed in a BioRad CFX Connect™ Optics Module thermal
cycler (Bio-Rad Laboratories Inc., Hercules, CA, USA). The Bio-Rad CFX Manager software was used to
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monitor the melting curve, and to obtain the quantification data. The relative mRNA expression of the
gene of interest was calculated with the ∆∆Ct method normalized to 18S RNA as a housekeeping gene.
4.5. MCP-1 ELISA
A human MCP-1 PicoKine™ ELISA kit (Boster Biological Technology, Pleasanton, CA, USA) was
used to quantify MCP-1 in cell culture supernatants according to the manufacturer’s instructions.
Confluent cells in 100 mm-diameter dishes were incubated for 4 h in DMEM serum-free prior to
stimulation with 1 nM TNFα. Cell supernatants were collected, centrifuged for 5 min at 14,000× g and
4 ◦C, and the supernatant was used in a 1:100 dilution.
4.6. Quantification of Sphingolipids by LC-MS/MS
Cell monolayers in 60 mm-diameter dishes were trypsinized, pelleted, and resuspended in
methanol containing C17-sphingolipids as internal standards and were subjected to lipid extraction
and LC-MS/MS analysis, as previously described [88].
4.7. Barrier Integrity Measurements Using the ECISTM System and Inflammatory Stimulus Preparation
The endothelial barrier integrity of the confluent HCMEC/D3 control and SPL-kd monolayers was
assessed using an electric cell-substrate impedance sensing (ECISTM) Zθ system (Applied Biophysics
Inc., Troy, NY, USA). ECIS is a real-time and impedance-based method to study the barrier dynamics
of cells grown onto gold-filmed wells. Semi-confluent HCMEC/D3 control and SPL-kd cells (passage
44–46) were seeded on 96W10idf ECIS CulturewareTM Arrays (Applied Biophysics Inc., Troy, NY,
USA), which were pre-coated with human fibronectin (1 mg/mL) and murine collagen IV (1.25 mg/mL)
in Hank’s balanced salt solution for 30–60 min. Partial media changes were performed every 24 h until
a steady state of resistance (approx. 1100–1400 Ω) was reached, corresponding with the development
of a confluent monolayer by the time stimulation experiments were commenced. ECIS experiments
were continuously monitored for 5–6 days to capture both acute and longer-term changes in the
endothelial resistance. The impedance of cell-covered electrodes was measured with the multiple
frequencies over time (MFT) mode to record the impedance measurements over a broad spectrum
of frequencies. The resistance represents the integrity of cell barriers and was monitored at 4000 Hz.
Each measurement was performed in triplicates. The time was resampled to 600 s and the medium
control was subtracted from the mean value of each measurement. In the barrier integrity experiments,
an inflammatory stimulus was used. The stock solution of the inflammatory stimulus (LPS + Cyt)
consisted of lipopolysaccharide (LPS, 10 µg/mL, E. coli O111:B4) and the pro-inflammatory cytokines
TNF-α (5 µg/mL), IL-1β (1 µg/mL), IFN-γ (1 µg/mL), and IL-6 (1 µg/mL) in DMEM/1% (w/v) BSA.
The cells were incubated with either 1:100, 1:400, 1:800, or 1:1000 LPS + Cyt dilutions. S1P was
solubilized in methanol and applied to cells in a final concentration of 10 nM or 100 nM as pre- (4 h
before LPS + Cyt) or post-treatment (24 h after LPS + Cyt).
4.8. Statistical Analysis
Statistical analysis was performed by one-way ANOVA or an unpaired t-test where applicable. For
multiple comparisons, the level of significance was calculated with Bonferroni correction. GraphPad
Prism Software, version 6, (San Diego, CA, USA) was used for statistical analysis and graph
presentations. For ECIS™ resistance curves, mean values and standard deviations were plotted
against time starting after LPS + Cyt or S1P stimulation. The statistics were verified as two-way
ANOVA withα= 0.05 and Bonferroni’s multiple comparisons test. The data are depicted as means± S.D.
for n number of replicates and are representatives from 3 independent experiments.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/4/1240/
s1.
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AMPKα adenosine monophosphate-activated protein kinase alpha
ANOVA analysis of variance
BBB blood-brain barrier
BSA bovine serum albumin
cDNA complementary deoxyribonucleic acid
CNS central nervous system
Ctrl control
DMEM Dulbecco’s modified Eagle medium
ECIS electric cell-substrate impedance sensing
ELISA enzyme-linked immunosorbent assay
eS1P extracellular sphingosine 1-phosphate
FBS fetal bovine serum
HCMEC/D3 human cerebral microvascular endothelial cells clone D3
HDAC histone deacetylase
ICAM-1 intercellular adhesion molecule 1
IL interleukin
INF-γ interferon gamma
iS1P intracellular sphingosine 1-phosphate
kd knockdown
KLF Krueppel-like factor
LC-MS/MS liquid chromatography–mass spectrometry
LPS lipopolysaccharide
LPS + Cyt LPS + cytokine mix
MAPK mitogen-activated protein kinase
MARCKS myristoylated alanine-rich C-kinase substrate
MCP-1 monocyte chemoattractant protein 1
mRNA messenger ribonucleic acid
NFkB nuclear factor kappa-light-chain-enhancer of activated B cells
PBS phosphate-buffered saline
PECAM-1 platelet and endothelial cell adhesion molecule 1
PKC protein kinase C
qPCR quantitative polymerase chain reaction
SAPK/JNK stress-activated protein kinase/c-Jun-N-terminal kinase
SD standard deviation
SDS-PAGE sodium dodecyl sulfate- polyacrylamide gel electrophoresis
shRNA short hairpin ribonucleic acid
SK sphingosine kinase
SPL/Sgpl1 sphingosine 1-phosphate lyase
TNFα tumor necrosis factor alpha
TPA 12-O-tetradecanoylphorbol-13-acetate
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TRAF2 TNF receptor-associated factor 2
VCAM-1 vascular cell adhesion molecule 1
VE-cadherin vascular endothelial cadherin
ZO-1 zonula occludens 1
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